glp 1 agonists and pancreatitis Reconciling GLP-1s GLP-1 Agonists and Pancreatitis Risk

Spread protein intake across three to four meals rather than loading it into one sitting, because the body can only utilize about 25-40 grams of protein per meal for muscle and tissue synthesis

Sources Castro R

Recent cryogenic electron microscope (cryo-EM) structures of the human and rabbit GLP-1Rs (bound to exendin-p5 and GLP-1, respectively) indicate that residue 33 does not interact with peptide agonists but extends towards solvent (Fig

Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)

HbA1c, hemoglobin A1c

For all pair wise comparisons, Risk ratios (RRs) and 95% Confidence Interval (CI) were used as the meta-analytic measure of association between treatment and the incidence of events